By J. Dolok. Regis College. 2018.
Thalidomide-dexametha- overall survival beneﬁt and no increased risk of second sone compared with melphalan-prednisolone in elderly patients malignancies with bortezomib-melphalan-prednisone versus with multiple myeloma order 100mg viagra soft amex erectile dysfunction books. Outcome initial therapy for multiple myeloma: a randomized Southwest according to cytogenetic abnormalities and DNA ploidy in Oncology Group trial (S0232) order 100mg viagra soft free shipping causes of erectile dysfunction in young adults. Age and organ dose dexamethasone as initial therapy for newly diagnosed damage correlate with poor survival in myeloma patients: multiple myeloma: an open-label randomised controlled trial. How to maintain patients on long-term therapy: Blood. Effect of CMP, carﬁlzomib nosed multiple myeloma patients: results from all randomized (CFZ) plus melphalan-prednisone (MP) on response rates in patients in the community-based, phase 3b UPFRONT study elderly patients with newly diagnosed multiple myeloma [abstract]. Patient-Reporte Quality of Life (QoL) in prednisone, and thalidomide in elderly patients with multiple elderly, newly diagnosed Multiple Myeloma (MM) patients myeloma: updated results of a randomized controlled trial. Randomized patients inthe community-based, phae 3b UP- 28. Blood (ASH Annual Meeting Ab- maintenance thalidomide therapy in multiple myeloma: MRC stracts). Maintenance in combination with lenalidomide and dexamethasone in pa- therapy with bortezomib plus thalidomide or bortezomib plus tients with previously untreated Multiple Myeloma (MM) prednisone in elderly multiple myeloma patients included in the [abstract]. McCarthy1 and Theresa Hahn1 1Roswell Park Cancer Institute, BMT Program, Department of Medicine, Buffalo, NY There have been major advances in the past decade in the continuum of therapy for transplantation-eligible multiple myeloma patients. For patients requiring therapy, recommended induction treatment consists of triple drug regimens followed by the collection of hematopoietic stem cells. The question of early versus delayed transplantation is under investigation and may identify patients for whom early transplantation is optimal therapy and those for whom it may be delayed. For transplantation-eligible patients, high-dose melphalan remains the standard regimen. After transplanta- tion, consolidation can be considered for patients with less than a complete remission. Maintenance therapy with bortezomib or lenalidomide (or both in very-high-risk patients) is a reasonable option for long-term disease control and improvement in overall survival. Incorporation of new agents into the continuum of multiple myeloma care should result in improved outcomes and long-term disease control. Introduction GEP and other molecular techniques, including next-generation Multiple myeloma (MM) is a malignant plasma cell proliferation sequencing and single nucleotide polymorphism arrays, are future that occurs within a spectrum of diseases that includes monoclonal strategies that could facilitate the systematic incorporation of new gammopathy of undetermined signiﬁcance, primary amyloidosis, therapies into the continuum of MM treatment. The development of nonsecretory myeloma, and solitary plasmacytoma. CRAB (which stands for “hyperCalcemia, Renal proved outcomes for all MM patients. Other indications include symptom- Induction regimens for MM patients requiring therapy have im- atic hyperviscosity, recurrent bacterial infections, and amyloidosis proved over the last decade. A recent report updated the continued with organ involvement. We review here the continuum of treat- improvement in survival for transplantation-eligible and transplanta- ment of the transplantation-eligible MM patient, including induc- 10 tion-ineligible MM patients over the past 10 years. Induction tion therapy, hematopoietic stem cell transplantation (HSCT), and regimens for transplantation-eligible MM patients have improved posttransplantation consolidation and maintenance. Induction regimens for transplantation-eligible patients are de- Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) signed to decrease the malignant plasma cell burden and improve 2 were ﬁrst used as salvage agents, then later as part of combination the depth of response. Depth of response after autologous transplan- induction therapy. The combination of an IMiD with a PI along with tation appears to correlate with the duration of disease control dexamethasone has resulted in marked improvements in disease before disease progression occurs with the need for salvage response. Improved depth of response has resulted in improved therapy. These risk factors included an IMiD or PI and increasing frequency; both drugs are will change over time as new agents are developed, which will used in combination with dexamethasone.
Due to the introduction of combination that com- pared the variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy discount 50mg viagra soft otc drugs for erectile dysfunction philippines, NHL was the AIDS-defining event with the great- est mortality hazard ratio (ART-CC 2009) viagra soft 50 mg online erectile dysfunction doctor toronto. Whether the clinical and pathological spec- trum of lymphoma subtypes is also changing remains unclear. A French study showed no differences in lymphoma features in antiretrovirally treated patients compared to treatment-naïve patients (Gérard 2009). However, it seems possible that, com- pared to HL or Burkitt’s lymphoma, the percentage of “opportunistic” NHL such as immunoblastic lymphoma will decrease. Prevention and early detection There is no data supporting specific therapies or diagnostic procedures (such as peri- odical ultrasound controls, etc) for prevention or for early detection of malignant lymphomas. Antiretroviral therapy seems to be the best protection against lym- phoma. ART not only improves the immune status but it also reduces the chronic B cell stimulation, another risk factor for the development of lymphoma (Grulich 2008). HIV plasma viremia should be as low as possible as cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving ART (Zoufaly 2009). Blood EBV DNA load also represents a risk factor (Leruez-Ville 2012). Besides ART, there have been numerous studies evaluating factors (so called “bio- markers”) that may precede the development of AIDS-associated lymphoma. For example, it has been shown that the levels of serum globulins (Grulich 2000), inter- 422 AIDS leukin-6 or -10 (Breen 2003), soluble CD33 (Pordue 2009, Breen 2012), activity of activation-induced cytidine deaminase (Epeldegui 2007) or circulating immuno- globulin-free light chains (Landgren 2009, Bibas 2013) may predict the risk of NHL. These activation markers were markedly elevated in those who developed AIDS- related NHL, when compared to AIDS patients and HIV-negative controls. These findings may help us understand the pathogenesis of lymphomas in HIV+ patients. However, a routine diagnostics measure has not been found. Signs and symptoms The main symptom is lymph node enlargement. Lymphomas are firm, immobile or barely mobile and painless. A large proportion of patients have advanced-stage lymphoma at the time of diagnosis. Ann Arbor stages III-IV are almost always the rule, and B symptoms with fever, night sweats and/or weight loss are found in the majority of cases (60–80%). General asthenia, significant malaise and rapid physical deterioration are also frequently seen. Extra-nodal involvement is common, and may be to a grotesque extent. In our own cohort of 203 patients, 81% had at least one extra-nodal focus (Hoffmann 2003). Every conceivable region of the body can be affected—the orbital cavity, testes, heart, breasts, bladder, kidneys, muscles, bones, etc. The gastrointestinal tract, liver, and bone marrow are affected particularly frequently. With extra-nodal disease, additional symptoms arise depending on the localization. These include, for example, abdominal pain from hepatosplenomegaly, hemorrhage or ileus symptoms due to intestinal involvement, bone pain with skeletal infiltration, or headache caused by brain disease. Diagnosis Rapid histological diagnosis is essential. If bone marrow biopsy cannot secure the diagnosis, then a lymph node (e. Mere puncture biopsy of a lymph node is often not sufficient to secure a rep- resentative specimen.
A series adverse risk factors purchase viagra soft 100 mg fast delivery erectile dysfunction medications for sale, speciﬁcally erythrocyte sedimentation rate from 1 center suggested that 6 cycles of ABVD was effective for 50 or 30 with B symptoms discount 50 mg viagra soft with visa erectile dysfunction at age 20, extranodal disease, more than 2 early-stage Hodgkin lymphoma, with only 6 recurrences among 71 sites of involvement, or mediastinal bulk disease. In the HD10 subjects with early favorable disease under the age of 45 and no study, a 2 2 factorial design used randomization between 2 and 4 deaths at a median follow-up of 5 years,26 although it is hard to cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarba- interpret such data in the absence of a control group. A small zine), followed by randomization between 20 and 30 Gy of randomized study in nonbulky stage I, II, and IIIA disease examined consolidation IFRT. The results in all the groups were excellent and 6 cycles of ABVD with or without consolidation IFRT, with no superimposable, with a projected 8-year freedom from treatment signiﬁcant difference in outcome among 152 patients entered, Hematology 2013 401 Table 2. Studies testing the omission of radiotherapy in early-stage Hodgkin lymphoma Median N follow-up, mo Treatment OS, y OS, % P FFTF/PFS/EFS, y FFTF/PFS/EFS, % P Memorial Sloan-Kettering Cancer 152 67 6 ABVD 5 90 NS 5 81 NS Center27 6 ABVD EFRT 97 86 North American Children’s Oncology 207 92 4 COPP-ABV 10 96 NS 10 83. There are particular reasons to avoid radiotherapy if possible among The largest study to make a direct comparison of chemotherapy children and young adults with Hodgkin lymphoma. These include alone with a combined modality approach was the intergroup study not only the higher cumulative risks of secondary malignancy and HD. For this reason, 2 pediatric oncology groups have in favorable early disease, or 2 cycles of ABVD followed by STNI examined chemotherapy-only approaches in randomized trials. The early report of this study, with a median the North American Children’s Oncology Group study CCG 5942, follow-up of 4. At that time, the OS was very good and not signiﬁcantly total of 498 patients received 4 cycles of COPP-ABV chemotherapy different between the arms (94% vs 96%, respectively), but a before randomization. Interestingly, 90% received radiotherapy (87% vs 94%, respectively; P. There was, however, no the arms, but the risk of death from other causes was more than difference in OS, with 10-year estimated survival rates of 97% and 3-fold higher among those irradiated, with much of the excess 96%, respectively, across all risk groups. When analyzing patients attributable to second cancers. The present-day relevance of this according to risk groups deﬁned by stage and the presence of risk study is limited by its use of EFRT, an approach that is no longer factors, the only subgroup to show a signiﬁcant difference in considered appropriate because it increases the irradiated volume 3- event-free survival was the favorable one, in which patients with to 5-fold and includes the mediastinum, with the risk of cardiac early-stage disease received less chemotherapy than the groups with disease; the axillae, with the risk of breast cancer; and the spleen, risk factors such as bulky disease or advanced stage. This difference with the risk of opportunistic infections. Perhaps the most interest- might be due to a preferential effect of radiotherapy when the disease is ing ﬁnding is that the control of Hodgkin lymphoma and OS can be localized or may be further evidence supporting an interaction between inﬂuenced in opposite directions such that the risk of progression the value of radiotherapy and the extent of prior chemotherapy. This highlights that freedom from Another study in younger patients was conducted by the German progression is a poor surrogate end point or proxy measure for the Pediatric Oncology and Hematology group (HD95). In that study, it was the intermediate-risk ABVD alone in comparable patients in the HD. For the PFS, however, the less favorable results after the omission of IFRT, with only a 68% difference did not reach signiﬁcance (HR 0. Only one secondary malignancy was seen among the 165 1. The difference between the patients who did not receive radiotherapy, whereas 17 occurred among treatments was particularly evident among patients who did not 746 patients who had radiotherapy (of these, 14 arose within the reach complete remission with initial chemotherapy (PFS; 402 American Society of Hematology Table 3. Five-point scale for the interpretation of interim FDG-PET has been extensively evaluated as a means to determine the degree scanning32 of response early during a course of treatment. A 5-point scale has Score PET/CT result been tested across multiple centers and shown to be reproducible in the evaluation of FDG-PET uptake32 (Table 3). In early Hodgkin 1 No uptake above background lymphoma, 3 prospective randomized studies have been performed 2 Uptake mediastinum 33,34 (Figure 1), of which 2 have so far presented early results. The 3 Uptake mediastinum but liver 4 Uptake moderately increased compared to the liver at any site designs of these studies are complementary, with different amounts 5 Uptake markedly increased compared to the liver at any site of treatment planned and different points of randomization, but all X New areas of uptake unlikely to be related to lymphoma intend to address the hypothesis that radiotherapy may be reserved for those patients found to have metabolically active sites of lymphoma on an interim FDG-PET scan and avoided for those in HR 0. Using functional imaging to modulate therapy In view of the information described, it would be helpful to have the The European Organisation for Research and Treatment of Cancer means to differentiate between patients likely to have been cured by (EORTC) H10 study recruited 1137 early-stage patients across both chemotherapy alone and those for whom the treatment has been less risk groups and after 2 cycles of ABVD patients were reported as effective and the risks of irradiation may be acceptable to improve PET negative in 85% of favorable and 74% of unfavorable cases in the chances of cure. There is considerable interest in the possible the control arm and in 88% and 78% of cases, respectively, in the role of FDG-PET scanning, which can be used in combination with experimental arm where radiotherapy would be omitted. This gives much greater sensitivity to the the experimental arm showed signiﬁcantly inferior PFS in the presence of viable Hodgkin lymphoma in small lymph nodes and favorable group (94.
All trials 64-66 best 50mg viagra soft best male erectile dysfunction pills over the counter, 68 67 enrolled patients with osteoarthritis of the knee or hand and ranged in duration from 4 65 66 best viagra soft 50mg erectile dysfunction protocol scam alert, 68 weeks to 12 weeks. Nonsteroidal antiinflammatory drugs (NSAIDs) 20 of 72 Final Report Update 4 Drug Effectiveness Review Project Among the trials of diclofenac 1. The purpose for including a very small amount of DMSO in the placebo solution was described as being for maintenance of blinding, as DMSO 65 has been associated with a garlic-like taste or odor. For the purpose of indirect comparison, we focused on the data from the placebo control group with the lower concentration of DMSO 65 (4. Efficacy outcomes in placebo-controlled trials of topical diclofenac drugs Diclofenac Pain scores: Topical OARSI response (% patients): Author Year topical drug drug vs. We also identified 5 additional placebo-controlled trials of the diclofenac epolamine 69 70 1. We excluded these trials because all had follow-up duration of less than 4 weeks. Efficacy: Comparisons between oral and topical drugs 74, We included 2 randomized controlled trials that compared an oral NSAID to a topical NSAID. In both trials, regardless of whether participants had bilateral knee osteoarthritis, only one knee was treated with the topical solution. Thus, efficacy assessments related to only the single treated knee. The first trial (N=622) evaluated equivalence between treatment with 50 drops (1. The second trial (N=755) was Nonsteroidal antiinflammatory drugs (NSAIDs) 21 of 72 Final Report Update 4 Drug Effectiveness Review Project designed to evaluate superiority of treatment with 40 drops (1. In the first trial, oral diclofenac showed greater mean changes in pain (−134 mm compared with −118 mm; P=0. In the second trial, there was no significant difference between topical and oral diclofenac in either than change in WOMAC pain (−6. Are there clinically important differences in short-term (< 6 months) or long-term (≥ 6 months) harms between NSAIDs, with or without antiulcer medication, when used in adults with chronic pain from osteoarthritis, rheumatoid arthritis, soft-tissue pain, back pain, or ankylosing spondylitis? Summary of Evidence Comparisons between oral drugs • Celecoxib compared with nonselective NSAIDs o With regard to upper gastrointestinal adverse events, celecoxib may offer a short- term advantage over nonselective NSAIDs, but this has not been conclusively demonstrated in longer-term (>6 months) studies o Short-term risk of clinically significant upper plus lower gastrointestinal events was significantly lower for celecoxib compared with diclofenac slow release plus omeprazole, primarily due to a lower risk of clinically significant decrease in hemoglobin due to presumed occult bleeding of gastrointestinal origin, including possible blood loss from the small bowel o Based on findings from 3 meta-analyses of randomized controlled trials that were primarily 12 weeks in duration, as well as in 1 large case-control study, risk of myocardial infarction for celecoxib was not significantly different compared with NSAIDs o No significant increase in risk of other cardiovascular events or cerebrovascular events was found for celecoxib as compared with nonselective NSAIDs in 6 meta- analyses of randomized controlled trials and 5 observational studies o With regard to cardiorenal harms, results from the longest-term CLASS trial and meta-analyses of shorter-term trials found no increased risk of hypertension or heart failure with celecoxib compared with nonselective NSAIDs o Celecoxib was not associated with an increased fracture risk in a fair-quality, large-scale, Danish population-based study • Partially selective NSAIDs o Meloxicam has not been conclusively demonstrated to offer an advantage over nonselective NSAIDs with regard to gastrointestinal adverse events; limited Nonsteroidal antiinflammatory drugs (NSAIDs) 22 of 72 Final Report Update 4 Drug Effectiveness Review Project evidence from observational studies has not suggested any increased risk for meloxicam in myocardial infarction, hepatotoxicity, or fracture o Compared with nonselective NSAIDs, nabumetone had a lower short-term risk of gastrointestinal perforation, symptomatic ulcer, or bleeding events, but long-term comparative risks are unknown; nabumetone was not associated with an increased fracture risk in a fair-quality, large-scale, Danish population-based study o Comparative short-term and long-term gastrointestinal risk for etodolac relative to nonselective NSAIDs has not been evaluated; a small increase in risk of fracture was found to be associated with recent use of etodolac (within 1 year) in a fair- quality, large-scale, Danish population-based study (adjusted relative risk, 1. Several older observational studies of salsalate were identified, but could not be used to contribute evidence about specific serious gastrointestinal and cardiovascular events due to limitations in outcome definition and methodology • No specific data was found on the comparative risks of serious cardiovascular or serious gastrointestinal effects for either tenoxicam or tiaprofenic acid compared with other NSAIDs; three observational studies reported cases of potentially serious cystitis in patients using tiaprofenic acid, particularly in patients >70 years old. Comparisons between topical drugs • We found no trials that directly compared harms between different topical drugs • Indirect evidence was only available from 1 placebo-controlled trial of diclofenac 1. Comparisons between oral and topical drugs • In 2 trials that directly compared diclofenac 1. Detailed Assessment Comparisons between oral drugs Adverse events evaluated included serious gastrointestinal events, cardiovascular risk, mortality, hypertension, congestive heart failure, edema, renal function, hepatotoxicity, and general tolerability. The majority of NSAID-related adverse effects have not appeared to be dependent upon long (>6 months) duration of exposure. The exception was cardiovascular risk, which was 27, 76-81 only been observed in trials with exposure periods that exceeded 8 months in duration. A continued important weakness of the available evidence was that long-term studies which simultaneously assess gastrointestinal, cardiac, and other serious adverse events were lacking, particularly for the nonselective NSAIDs, thus seriously limiting our ability to accurately determine the true balance of overall benefits and harms. Celecoxib compared with nonselective NSAIDs (with and without antiulcer medication) Celecoxib is currently the only COX-2 inhibitor available in the United States. The Agency for Healthcare Research and Quality Effective Health Care Comparative Effectiveness Review is the most comprehensive review to date of the comparative safety of celecoxib relative to other 31 NSAIDs, placebo, or nonuse. Conclusions of the review were based on numerous meta- 27, 32, 33, 79, 81-91 analyses of primarily short-term randomized controlled trials (7 months or less) 92-102 and population based observational studies. Nonsteroidal antiinflammatory drugs (NSAIDs) 24 of 72 Final Report Update 4 Drug Effectiveness Review Project With regard to upper gastrointestinal adverse events celecoxib seemed to offer a short- term advantage over nonselective NSAIDs, when neither were taken with antiulcer medication, but this has not been conclusively demonstrated in longer-term (>6 months) studies. CLASS 27 remains the longest-term trial to date of patients with osteoarthritis/rheumatoid arthritis. Results from an interim, 6-month analysis from the CLASS trial (32/3987 compared with 51/3981, 27 annualized incidence rates 2. In a meta-analysis of 14 randomized controlled trials from 2000, annual rates of upper gastrointestinal ulcer complications were 2 per 1000 yearly for celecoxib 83 and about 17 per 1000 yearly for NSAIDs (P=0.
9 of 10 - Review by J. Dolok
Votes: 252 votes
Total customer reviews: 252